Werewolf Therapeutics posts $9.9 million Q3 2026 net loss
Revenue was zero while operating expenses fell to $10.1 million; it ended the quarter with $41.9 million in cash and cites substantial going-concern doubt.
See the latest news and media coverage for Werewolf. We track all announcements, press releases, and industry mentions in real time, all in one place.
Cancer immunotherapy biotechnology company
werewolftx.comLast updated
In short: Werewolf Therapeutics advanced its Ambros merger, shared oncology trial data, and reported a $9.9 million Q3 loss.
Revenue was zero while operating expenses fell to $10.1 million; it ended the quarter with $41.9 million in cash and cites substantial going-concern doubt.
The combined company, valued at about $697.5M, will be renamed Ambros Therapeutics and trade as AMBX, backed by a $150M PIPE.
Phase 1/1b WTX-124 data show durable antitumor activity, and Werewolf aligned with the FDA on an 18 mg recommended Phase 2 dose. WTX-330 was well tolerated.
The filing solicits stockholder approval for a merger where Werewolf becomes a subsidiary of Ambros Therapeutics, valued at $500 million.
Werewolf's WTX-330 shows partial response in early cancer trial, demonstrating manageable tolerability across dose escalation ...
In August 2026, Nasdaq-listed Werewolf Therapeutics (which was running low on cash and had previously been reported to be considering a sale or merger) announced a reverse merger with Ambros Therapeutics, which specializes in rare disease drugs, raising $150 million simultaneously. Following the merger, Ambros will take the lead, with former Ambros shareholders holding approximately 71.7% of the shares, while former Werewolf shareholders will hold only 6.8%. A so-called reverse merger allows a small company to go public directly by using an already listed company's status, avoiding the need to go through the IPO queue process again—although the shares are significantly diluted...
Two law firms are investigating the valuation process; the merger and $150 million private placement still require approvals.
Biopharmaceutical company Werewolf Therapeutics and clinical-stage biotechnology firm Ambros Therapeutics have agreed to merge in an all-stock deal built by three law firms, and includes...
Track Werewolf and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Werewolf and other trending companies.